Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD)

11 Nov 2020 10:58

RNS Number : 9834E
Horizon Discovery Group plc
11 November 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Horizon Discovery Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Horizon Discovery Group plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

10 November 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

 

TOTAL:

Nil

Nil

Nil

Nil

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a) Holdings of ordinary shares of 1p each in Horizon Discovery Group plc by directors and their close relatives

 

Name

No. of ordinary shares held

Percentage of issued share capital

Terry Pizzie

42,285

0.03%

Jayesh Pankhania

90,768

0.06%

Ian Gilham

145,592

0.09%

Grahame Cook

142,250

0.09%

Susan Searle

90,000

0.06%

Vishal Gulati

14,100

0.01%

 

b) The Directors hold the following number of options to acquire ordinary shares in the Company:

 

Name

No. of share options held

Ian Gilham

143,250

Terry Pizzie

1,245,818

Jayesh Pankhania

666,550

Dr Siddhartha Kadia

150,000

 

 

1) Ian Gilham

 

EMI Scheme

 

Options granted

Grant Price

Grant Date

Vest Date

Expiry Date

57,300

£0.6774

18-Oct-2013

18-Oct-2017

18-Oct-2023

85,950

£0.8726

18-Mar-2014

18-Mar-2017

18-Mar-2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2) Terry Pizzie

 

Long Term Incentive Plan

 

Options granted

Grant Price

Grant Date

Vest quant 1

Vest Date 1

Vest quant 2

Vest date 2

Vest quant 3

Vest date 3

Expiry Date

60,185

£1.62

07-Apr-2017

60,185

07-Apr-2020

07-Apr-2027

7,812

£0.01

01-Nov-2017

2,604

01-Nov-2018

2,604

01-Nov-2019

2,604

01-Nov-2020

01-Nov-2027

15,031

£1.57

10-May-2018

5,010

10-May-2019

5,010

10-May-2020

5,011

10-May-2021

10-May-2028

41,401

£0.01

10-May-2018

13,800

10-May-2020

13,800

10-May-2021

13,801

10-May-2022

10-May-2028

3,199

£2.00

09-Nov-2018

799

09-Nov-2021

800

09-Nov-2022

1,600

09-Nov-2023

09-Nov-2028

321,801

£2.00

09-Nov-2018

80,450

09-Nov-2021

80,450

09-Nov-2022

160,901

09-Nov-2023

09-Nov-2028

624,594

£1.64

26-Feb-2020

624,594

26-Feb-2023

26-Feb-2030

85,863

£0.01

26-Feb-2020

42,932

26-Feb-2022

42,931

26-Feb-2023

26-Feb-2030

70,730

£0.01

15-Mar-2019

35,365

15-Mar-2021

35,365

15-Mar-2022

15-Mar-2029

 

Sharesave

 

Options granted

Grant Price

Grant Date

Vest Date

Expiry Date

15,202

£1.184

05-Jul-2019

01-Sep-2022

01-Mar-2023

 

3) Jayesh Pankhania

 

Long Term Incentive Plan

 

Options granted

Grant Price

Grant Date

Vest quant 1

Vest Date 1

Vest quant 2

Vest date 2

Vest quant 3

Vest date 3

Expiry Date

17,167

£1.7475

06-Feb-2019

4,291

06-Feb-2022

4,292

06-Feb-2023

8,584

06-Feb-2024

06-Feb-2029

111,588

£1.7475

06-Feb-2019

27,897

06-Feb-2022

27,897

06-Feb-2023

55,794

06-Feb-2024

06-Feb-2029

45,064

£0.01

06-Feb-2019

15,021

06-Feb-2021

15,022

06-Feb-2022

15,021

06-Feb-2023

06-Feb-2029

419,817

£1.64

26-Feb-2020

419,817

26-Feb-2023

26-Feb-2030

57,712

£0.01

26-Feb-2020

28,856

26-Feb-2022

28,856

26-Feb-2023

26-Feb-2030

 

Sharesave

 

Options granted

Grant Price

Grant Date

Vest Date

Expiry Date

15,202

£1.184

05-Jul-2019

01-Sep-2022

01-Mar-2023

 

 

 

 

4) Dr Siddhartha Kadia

Long Term Incentive Plan

 

Options granted

Grant Price

Grant Date

Vest quant 1

Vest Date 1

Vest quant 2

Vest date 2

Vest quant 3

Vest date 3

Expiry Date

150,000

£1.03

18-Jun-2020

50,000

18-Jun-2021

50,000

18-Jun-2022

50,000

18-Jun-2023

18-Jun-2030

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

11 November 2020

Contact name:

Teifion Hill

Telephone number:

 01223 976000

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEFFWFSFESSEIF
Date   Source Headline
25th Mar 20157:00 amRNSHorizon Discovery awarded AMSCI grant
24th Mar 20157:00 amRNSNotice of Preliminary Results
23rd Mar 20157:00 amRNSHorizon Discovery and ArcherDX Sign OEM Agreement
18th Mar 201510:39 amRNSAdditional Listing
11th Mar 20157:00 amRNSHorizon Provides Genomic Standards To CRUK
18th Feb 20157:00 amRNSInnovate UK funding award
11th Feb 20154:27 pmRNSAdditional Listing
5th Feb 201512:21 pmRNSAdditional Listing
2nd Feb 20157:00 amRNSHorizon Discovery Selected as Core Facility
27th Jan 201512:00 pmRNSAdditional Listing
23rd Jan 20154:46 pmRNSHolding(s) in Company
19th Jan 20157:00 amRNSRevenues expected to be ahead of consensus by 7%
15th Jan 20157:00 amRNSHolding(s) in Company
8th Jan 20157:00 amRNSAcquisition of Haplogen Genomics GmbH
30th Dec 20147:00 amRNSHorizon Discovery Group Signs Agreement for $810K
22nd Dec 20144:49 pmRNSAdditional Listing
19th Dec 20146:23 pmRNSHolding(s) in Company
8th Dec 20147:00 amRNSLaunch of Gene-Engineered Bioproduction Cell Line
26th Nov 20143:09 pmRNSHolding(s) in Company
24th Nov 20147:00 amRNSHorizon Enter Agreement with Adarza BioSystems
19th Nov 201412:26 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNS$750,000 contract win from top ten pharma
3rd Nov 20147:00 amRNSAppoints Dr David Smoller as an Executive Director
15th Oct 20147:00 amRNSHorizon CombinatoRx Wins Contract
6th Oct 20143:14 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Oct 20147:00 amRNSCo-Exclusive Commercial Agreement Signed
29th Sep 20147:00 amRNSAcquires Sage Labs Inc. for $48M (£29M)
25th Sep 201412:30 pmRNSAdditional Listing
25th Sep 20147:00 amRNS$1.2 million Master Services Agreement
23rd Sep 20147:00 amRNSInterim Results for Six Months Ended 30 June 2014
17th Sep 20144:34 pmRNSHolding(s) in Company
15th Sep 20145:29 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
5th Sep 201410:17 amRNSAdditional Listing
3rd Sep 20147:00 amRNSNotice of Interim Results
5th Aug 20147:00 amRNSCRISPR Experts Join Scientific Advisory Board
28th Jul 20143:57 pmRNSAdditional Listing
25th Jul 20147:00 amRNSHZD sign Collaboration Agreement with Otsuka
23rd Jul 20147:00 amRNSTrading Update
3rd Jul 20147:00 amRNSLicenses AAV Gene Delivery Technology
19th Jun 201410:48 amRNSDirector/PDMR Shareholding
17th Jun 20143:35 pmRNSAdditional Listing
16th Jun 20147:00 amRNSTSB Grant for next generation cancer diagnostics
12th Jun 20147:00 amRNSLicenses CRISPR Technology from Broad Institute
11th Jun 201412:11 pmRNSDirector/PDMR Shareholding
9th Jun 20147:00 amRNSAppointment of two Non-Executive Directors
2nd Jun 20147:00 amRNSCompletion of Acquisition of CombinatoRx
15th May 20147:00 amRNSAcquisition
8th May 20147:00 amRNSHolding in Company
8th May 20147:00 amRNSLicenses Gene Editing Technology from ERS Genomics
6th May 20145:48 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.